Compare SoFi Technologies Inc (SOFI) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
SoFi Technologies Inc vs Twist Bioscience Corp — how do they compare? SoFi Technologies Inc trades at $17.61 (market cap $21.82B), while Twist Bioscience Corp trades at $88.31 (market cap $5.45B). The key difference: SoFi Technologies Inc is far larger — about 4× Twist Bioscience Corp's market cap, and Twist Bioscience Corp is trading nearer its 52-week high, SoFi Technologies Inc nearer its low. Which is the better fit depends on your goals.
| SOFI | TWST | |
|---|---|---|
Market Cap | $21.82B | $5.45B |
Sector | Financials | Health |
52-Week High | $32.21 | $102.88 |
52-Week Low | $15.15 | $24.16 |
Enterprise Value | — | $5.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SoFi Technologies (SOFI) trades at $17.64, up 2.08% today, amid a bearish technical signal but strong recent earnings beats. The stock is near its consensus price target low of $17.00, with revenue growth accelerating to $3.61 billion in 2025 and a net income margin of 13.32%. Cash flow trends show heavy reliance on financing activities, while assets have grown to $36.25 billion as of 2024. Recent news highlights upcoming Q2 2026 earnings on July 29, with management guiding for 30% top-line growth.
The outlook for SOFI hinges on sustained revenue expansion and profitability improvements, but risks include negative operating cash flows and competitive pressures. Analyst sentiment is mixed with a 33.33% buy rating, suggesting cautious optimism if execution meets guidance. The stock presents a potential opportunity if Q2 earnings beat expectations, yet volatility remains high given its fintech exposure and macroeconomic sensitivity.
TWST trades at $95.86, up 2.14% today, with a bullish technical signal and strong institutional interest. Revenue growth is robust, rising from $204M in 2022 to $377M in 2025, though the company remains unprofitable with a net income margin of -19.85%. Recent news highlights AI-driven collaborations and earnings beats, but cash flow trends show persistent operational losses.
The outlook is mixed; analyst consensus is bullish with a $91.63 price target, but profitability challenges and negative cash flows pose significant risks. Investment opportunity lies in continued revenue expansion and AI partnerships, while execution risks and high valuations require caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About SoFi Technologies Inc
SoFi is a financial services company that was founded in 2011 and is currently based in San Francisco. Initially known for its student loan refinancing business, the company has expanded its product offerings to include personal loans, credit cards, mortgages, investment accounts, banking services, and financial planning. The company intends to be a one-stop shop for its clients' finances and operates solely through its mobile app and website. Through its acquisition of Galileo in 2020 the company also offers payment and account services for debit cards and digital banking.
Read more on SOFI →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
